CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,258 enrolled
Drug / intervention
Japanese Encephalitis purified inactivated vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00596102
NCT00596102N/ACompleted
CompareCT.gov

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51. An Uncontrolled Phase 3 Follow-up Study

Valneva Austria GmbH·observational·Posted Jan 16, 2008·Updated Jul 30, 2014

In Brief

An observational study evaluating Japanese Encephalitis purified inactivated vaccine for Japanese Encephalitis. Completed, enrolled 3,258 participants.

Detailed Summary

The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 16, 2008
Enrollment StartOct 1, 2005
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 18.5 years ago

Interventions

Japanese Encephalitis purified inactivated vaccinebiological

Japanese Encephalitis purified inactivated vaccine